Melanoma Clinical Trials in Minneapolis

Showing 161-180 of 212 trials

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

NCT03297463

This is a Phase 1b/2 study designed to evaluate combination of the human T-cell cytokine Interleukin-2 (IL-2) and a checkpoint inhibitor Ipilimumab immediately following a course of hypofractionated palliative radiation therapy in the management of unresectable, relapsed/refractory metastatic melanoma.

Metastatic MelanomaPulmonary MetastasesHepatic Metastases+1 more

Masonic Cancer Center, University of MinnesotaStarted Jan 2018

Minneapolis, Minnesota, United States

TERMINATEDPhase 3< 1 mile

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

NCT01006252

The primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.

Melanoma

Eli Lilly and Company336 participantsStarted Dec 2009

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Tucson, Arizona, United States +119 more locations

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

Melanoma Trials in Other Cities

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Everolimus in Treating Patients With Stage IV Melanoma

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

A Study of Vemurafenib in Participants With Metastatic Melanoma

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Other Conditions in Minneapolis